Description Cancer patients need access to promising investigational therapies, available only through clinical trials, and the emergence of COVID-19 and the resulting pandemic became an emerging threat to fulfilling that need. Many academic medical centers were pausing their clinical research programs, diverting their resources and sheltering their teams. Sarah Cannon, the Cancer Institute of HCA Healthcare, made the decision to stay safe, but stay the course.
Keywords: COVID-19; SARS-CoV-2; biomedical research; clinical trials as topic; neoplasms; pandemics; telemedicine.
© 2020 HCA Physician Services, Inc. d/b/a Emerald Medical Education.